137 related articles for article (PubMed ID: 34088869)
1. EMT-Derived Alterations in Glutamine Metabolism Sensitize Mesenchymal Breast Cells to mTOR Inhibition.
Karvelsson ST; Sigurdsson A; Seip K; Grinde MT; Wang Q; Johannsson F; Mælandsmo GM; Moestue SA; Rolfsson O; Halldorsson S
Mol Cancer Res; 2021 Sep; 19(9):1546-1558. PubMed ID: 34088869
[TBL] [Abstract][Full Text] [Related]
2. Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2) Is Upregulated in Breast Epithelial-Mesenchymal Transition and Responds to Oxidative Stress.
Wang Q; Karvelsson ST; Kotronoulas A; Gudjonsson T; Halldorsson S; Rolfsson O
Mol Cell Proteomics; 2022 Feb; 21(2):100185. PubMed ID: 34923141
[TBL] [Abstract][Full Text] [Related]
3. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT).
Martin FT; Dwyer RM; Kelly J; Khan S; Murphy JM; Curran C; Miller N; Hennessy E; Dockery P; Barry FP; O'Brien T; Kerin MJ
Breast Cancer Res Treat; 2010 Nov; 124(2):317-26. PubMed ID: 20087650
[TBL] [Abstract][Full Text] [Related]
4. Two Novel Tri-Aryl Derivatives Attenuate the Invasion-Promoting Effects of Stromal Mesenchymal Stem Cells on Breast Cancer.
Moradi K; Barneh F; Irian S; Amini M; Moradpoor R; Amanzadeh A; Choopani S; Rahimi H; Ghodselahi T; Boujar MM; Salimi M
Anticancer Agents Med Chem; 2019; 19(8):1002-1011. PubMed ID: 30747082
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transition induces similar metabolic alterations in two independent breast cancer cell lines.
Kondaveeti Y; Guttilla Reed IK; White BA
Cancer Lett; 2015 Aug; 364(1):44-58. PubMed ID: 25917568
[TBL] [Abstract][Full Text] [Related]
6. Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition.
Halldorsson S; Rohatgi N; Magnusdottir M; Choudhary KS; Gudjonsson T; Knutsen E; Barkovskaya A; Hilmarsdottir B; Perander M; Mælandsmo GM; Gudmundsson S; Rolfsson Ó
Cancer Lett; 2017 Jun; 396():117-129. PubMed ID: 28323032
[TBL] [Abstract][Full Text] [Related]
7. EMT-induced metabolite signature identifies poor clinical outcome.
Bhowmik SK; Ramirez-Peña E; Arnold JM; Putluri V; Sphyris N; Michailidis G; Putluri N; Ambs S; Sreekumar A; Mani SA
Oncotarget; 2015 Dec; 6(40):42651-60. PubMed ID: 26315396
[TBL] [Abstract][Full Text] [Related]
8. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
9. Metformin Treatment or PRODH/POX-Knock out Similarly Induces Apoptosis by Reprograming of Amino Acid Metabolism, TCA, Urea Cycle and Pentose Phosphate Pathway in MCF-7 Breast Cancer Cells.
Huynh TYL; Oscilowska I; Sáiz J; Nizioł M; Baszanowska W; Barbas C; Palka J
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944532
[TBL] [Abstract][Full Text] [Related]
10. CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression.
Li L; Liu C; Amato RJ; Chang JT; Du G; Li W
Oncotarget; 2014 Nov; 5(21):10840-53. PubMed ID: 25333262
[TBL] [Abstract][Full Text] [Related]
11. Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch.
Lee SY; Jeon HM; Ju MK; Jeong EK; Kim CH; Park HG; Han SI; Kang HS
Oncotarget; 2016 Feb; 7(7):7925-39. PubMed ID: 26771232
[TBL] [Abstract][Full Text] [Related]
12. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.
Li JP; Yang YX; Liu QL; Zhou ZW; Pan ST; He ZX; Zhang X; Yang T; Pan SY; Duan W; He SM; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1027-62. PubMed ID: 25733818
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
[TBL] [Abstract][Full Text] [Related]
14. Bone metastatic breast cancer cells display downregulation of PKC-ζ with enhanced glutamine metabolism.
Tandon M; Othman AH; Winogradzki M; Pratap J
Gene; 2021 Apr; 775():145419. PubMed ID: 33444686
[TBL] [Abstract][Full Text] [Related]
15. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M
BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells.
Maroufi NF; Amiri M; Dizaji BF; Vahedian V; Akbarzadeh M; Roshanravan N; Haiaty S; Nouri M; Rashidi MR
Eur J Pharmacol; 2020 Aug; 881():173282. PubMed ID: 32580038
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
[TBL] [Abstract][Full Text] [Related]
18. Glutamine metabolism in breast cancer and possible therapeutic targets.
Li S; Zeng H; Fan J; Wang F; Xu C; Li Y; Tu J; Nephew KP; Long X
Biochem Pharmacol; 2023 Apr; 210():115464. PubMed ID: 36849062
[TBL] [Abstract][Full Text] [Related]
19. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Brown WS; Akhand SS; Wendt MK
Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
[TBL] [Abstract][Full Text] [Related]
20. Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: systems analysis of molecular changes and their effect on radiation and drug sensitivity.
Mezencev R; Matyunina LV; Jabbari N; McDonald JF
BMC Cancer; 2016 Mar; 16():236. PubMed ID: 26988558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
